Advances and challenges in developing a therapy for spinal muscular atrophy

References

• Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000;15(3):228-37
   PubMed Web of Science ®Google Scholar
• Wirth B, Herz M, Wetter A, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet 1999;64(5):1340-56
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80(1):155-65
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008;133(4):585-600
   PubMed Web of Science ®Google Scholar
• Anderton RS, Meloni BP, Mastaglia FL, Boulos S. Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein. Mol Neurobiol 2013;47(2):821-32
   Google Scholar
• Kariya S, Park GH, Maeno-Hikichi Y, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 2008;17(16):2552-69
   PubMed Web of Science ®Google Scholar
• Boon KL, Xiao S, McWhorter ML, et al. Zebrafish survival motor neuron mutants exhibit presynaptic neuromuscular junction defects. Hum Mol Genet 2009;18(19):3615-25
   Google Scholar
• van Bergeijk J, Rydel-Konecke K, Grothe C, Claus P. The spinal muscular atrophy gene product regulates neurite outgrowth: importance of the C terminus. FASEB J 2007;21(7):1492-502
   PubMed Web of Science ®Google Scholar
• Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007;22(8):1027-49
   PubMed Web of Science ®Google Scholar
• Munsat TL, Davies KE. International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord 1992;2(5-6):423-8
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012;11(5):443-52
   PubMed Web of Science ®Google Scholar
• Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995;52(5):518-23
   Google Scholar
• Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics 2004;114(5):e548-53
   PubMed Web of Science ®Google Scholar
• Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007;22(8):946-51
   PubMed Web of Science ®Google Scholar
• Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008;371(9630):2120-33
   PubMed Web of Science ®Google Scholar
• Prior TW. Perspectives and diagnostic considerations in spinal muscular atrophy. Genet Med 2010;12(3):145-52
   Google Scholar
• Alias L, Bernal S, Fuentes-Prior P, et al. Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. Hum Genet 2009;125(1):29-39
   Google Scholar
• Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999;96(11):6307-11
   PubMed Web of Science ®Google Scholar
• Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999;8(7):1177-83
   PubMed Web of Science ®Google Scholar
• Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002;30(4):377-84
   PubMed Web of Science ®Google Scholar
• Harada Y, Sutomo R, Sadewa AH, et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J Neurol 2002;249(9):1211-19
   Google Scholar
• Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005;57(5):704-12
   PubMed Web of Science ®Google Scholar
• Amara A, Adala L, Ben Charfeddine I, et al. Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients. Eur J Paediatric Neurol 2012;16(2):167-74
   Google Scholar
• Chen Q, Baird SD, Mahadevan M, et al. Sequence of a 131-kb region of 5q13.1 containing the spinal muscular atrophy candidate genes SMN and NAIP. Genomics 1998;48(1):121-7
   Google Scholar
• Roy N, Mahadevan MS, McLean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995;80(1):167-78
   Google Scholar
• Watihayati MS, Zabidi AM, Tang TH, et al. NAIP-deletion analysis in Malaysian patients with spinal muscular atrophy. Kobe J Med Sci 2007;53(4):171-5
   Google Scholar
• Watihayati MS, Fatemeh H, Marini M, et al. Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy. Brain Dev 2009;31(1):42-5
   PubMed Web of Science ®Google Scholar
• Stratigopoulos G, Lanzano P, Deng L, et al. Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol 2010;67(10):1252-6
   Google Scholar
• Yanyan C, Yujin Q, Jinli B, et al. Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy. J Hum Genet 2014;59(1):24-7
   Google Scholar
• Lorson CL, Strasswimmer J, Yao JM, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998;19(1):63-6
   PubMed Web of Science ®Google Scholar
• Burlet P, Huber C, Bertrandy S, et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet 1998;7(12):1927-33
   Google Scholar
• Tizzano EF, Cabot C, Baiget M. Cell-specific survival motor neuron gene expression during human development of the central nervous system: implications for the pathogenesis of spinal muscular atrophy. Am J Pathol 1998;153(2):355-61
   Google Scholar
• Soler-Botija C, Ferrer I, Gich I, et al. Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain 2002;125(Pt 7):1624-34
   Google Scholar
• Fan L, Simard LR. Survival motor neuron (SMN) protein: role in neurite outgrowth and neuromuscular maturation during neuronal differentiation and development. Hum Mol Genet 2002;11(14):1605-14
   Google Scholar
• Simic G, Mladinov M, Seso Simic D, et al. Abnormal motoneuron migration, differentiation, and axon outgrowth in spinal muscular atrophy. Acta Neuropathol 2008;115(3):313-26
   PubMed Web of Science ®Google Scholar
• Murray LM, Lee S, Baumer D, et al. Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 2010;19(3):420-33
   Google Scholar
• McGovern VL, Gavrilina TO, Beattie CE, Burghes AH. Embryonic motor axon development in the severe SMA mouse. Hum Mol Genet 2008;17(18):2900-9
   Google Scholar
• Kerr DA, Nery JP, Traystman RJ, et al. Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci USA 2000;97(24):13312-17
   PubMed Web of Science ®Google Scholar
• Simic G, Seso-Simic D, Lucassen PJ, et al. Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann disease. J Neuropathol Exp Neurol 2000;59(5):398-407
   Google Scholar
• Parker GC, Li X, Anguelov RA, et al. Survival motor neuron protein regulates apoptosis in an in vitro model of spinal muscular atrophy. Neurotox Res 2008;13(1):39-48
   Google Scholar
• Anderton RS, Meloni BP, Mastaglia FL, et al. Survival of motor neuron protein over-expression prevents calpain-mediated cleavage and activation of procaspase-3 in differentiated human SH-SY5Y cells. Neuroscience 2011;181:226-33
   PubMed Web of Science ®Google Scholar
• Anderton RS, Price LL, Turner BJ, et al. Co-regulation of survival of motor neuron and Bcl-xL expression: implications for neuroprotection in spinal muscular atrophy. Neuroscience 2012;220:228-36
   Google Scholar
• Vyas S, Bechade C, Riveau B, et al. Involvement of survival motor neuron (SMN) protein in cell death. Hum Mol Genet 2002;11(22):2751-64
   Google Scholar
• Iwahashi H, Eguchi Y, Yasuhara N, et al. Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature 1997;390(6658):413-17
   PubMed Web of Science ®Google Scholar
• Young PJ, Day PM, Zhou J, et al. A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. J Biol Chem 2002;277(4):2852-9
   Google Scholar
• Battle DJ, Kasim M, Yong J, et al. The SMN complex: an assembly machine for RNPs. Cold Spring Harb Symp Quant Biol 2006;71:313-20
   PubMedGoogle Scholar
• Raker VA, Hartmuth K, Kastner B, Luhrmann R. Spliceosomal U snRNP core assembly: Sm proteins assemble onto an Sm site RNA nonanucleotide in a specific and thermodynamically stable manner. Mol Cell Biol 1999;19(10):6554-65
   PubMedGoogle Scholar
• Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Exp Cell Res 2004;296(1):51-6
   Google Scholar
• Pellizzoni L. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep 2007;8(4):340-5
   PubMed Web of Science ®Google Scholar
• Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN complex. J Child Neurol 2007;22(8):990-4
   PubMed Web of Science ®Google Scholar
• Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996;15(14):3555-65
   PubMed Web of Science ®Google Scholar
• Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997;90(6):1013-21
   PubMed Web of Science ®Google Scholar
• Charroux B, Pellizzoni L, Perkinson RA, et al. Gemin3: A novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems. J Cell Biol 1999;147(6):1181-94
   Google Scholar
• Charroux B, Pellizzoni L, Perkinson RA, et al. Gemin4. A novel component of the SMN complex that is found in both gems and nucleoli. J Cell Biol 2000;148(6):1177-86
   PubMed Web of Science ®Google Scholar
• Baccon J, Pellizzoni L, Rappsilber J, et al. Identification and characterization of Gemin7, a novel component of the survival of motor neuron complex. J Biol Chem 2002;277(35):31957-62
   Google Scholar
• Gubitz AK, Mourelatos Z, Abel L, et al. Gemin5, a novel WD repeat protein component of the SMN complex that binds Sm proteins. J Biol Chem 2002;277(7):5631-6
   PubMed Web of Science ®Google Scholar
• Pellizzoni L, Yong J, Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 2002;298(5599):1775-9
   PubMed Web of Science ®Google Scholar
• Carissimi C, Saieva L, Baccon J, et al. Gemin8 is a novel component of the survival motor neuron complex and functions in small nuclear ribonucleoprotein assembly. J Biol Chem 2006;281(12):8126-34
   PubMed Web of Science ®Google Scholar
• Will CL, Luhrmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol 2001;13(3):290-301
   PubMed Web of Science ®Google Scholar
• Kolb SJ, Sutton S, Schoenberg DR. RNA processing defects associated with diseases of the motor neuron. Muscle Nerve 2010;41(1):5-17
   Google Scholar
• Lotti F, Imlach WL, Saieva L, et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell 2012;151(2):440-54
   PubMed Web of Science ®Google Scholar
• Sleigh JN, Gillingwater TH, Talbot K. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Models Mech 2011;4(4):457-67
   Google Scholar
• Bowerman M, Shafey D, Kothary R. Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J Mol Neurosci 2007;32(2):120-31
   PubMed Web of Science ®Google Scholar
• Nolle A, Zeug A, van Bergeijk J, et al. The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum Mol Genet 2011;20(24):4865-78
   PubMed Web of Science ®Google Scholar
• Bowerman M, Beauvais A, Anderson CL, Kothary R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum Mol Genet 2010;19(8):1468-78
   PubMed Web of Science ®Google Scholar
• Li XM, Dong XP, Luo SW, et al. Retrograde regulation of motoneuron differentiation by muscle beta-catenin. Nat Neurosci 2008;11(3):262-8
   Google Scholar
• Wishart TM, Mutsaers CA, Riessland M, et al. Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy. J Clin Invest 2014;124(4):1821-34
   PubMed Web of Science ®Google Scholar
• Allen E, Ding J, Wang W, et al. Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. Nature 2005;438(7065):224-8
   Google Scholar
• Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harbor Perspect Biol 2012;4(12):a008771
   Google Scholar
• Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011;478(7367):123-6
   PubMed Web of Science ®Google Scholar
• Rudnik-Schoneborn S, Heller R, Berg C, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet 2008;45(10):635-8
   PubMed Web of Science ®Google Scholar
• Wang CH, Lunn MR. Spinal muscular atrophy: advances in research and consensus on care of patients. Curr Treat Options Neurol 2008;10(6):420-8
   PubMedGoogle Scholar
• Wishart TM, Huang JP, Murray LM, et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 2010;19(21):4216-28
   Google Scholar
• Zhang Z, Pinto AM, Wan L, et al. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy. Proc Natl Acad Sci USA 2013;110(48):19348-53
   PubMed Web of Science ®Google Scholar
• MacLeod MJ, Taylor JE, Lunt PW, et al. Prenatal onset spinal muscular atrophy. Eur J Paediatric Neurol 1999;3(2):65-72
   Google Scholar
• Bebee TW, Gladman JT, Chandler DS. Generation of a tamoxifen inducible SMN mouse for temporal SMN replacement. Genesis 2011;49(12):927-34
   Google Scholar
• Lutz CM, Kariya S, Patruni S, et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011;121(8):3029-41
   PubMed Web of Science ®Google Scholar
• Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28(3):271-4
   PubMed Web of Science ®Google Scholar
• Hao le T, Duy PQ, Jontes JD, et al. Temporal requirement for SMN in motoneuron development. Hum Mol Genet 2013;22(13):2612-25
   Google Scholar
• Kariya S, Obis T, Garone C, et al. Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest 2014;124(2):785-800
   PubMed Web of Science ®Google Scholar
• Francis JW, Figueiredo D, vanderSpek JC(et al):A survival motor neuron: tetanus toxin fragment C fusion protein for the targeted delivery of SMN protein to neurons. Brain Res 2004;995(1):84-96
   Google Scholar
• Anderton R, Meloni B, Mastaglia F, Boulos S. Investigation of a recombinant SMN protein delivery system to treat spinal muscular atrophy. Transl Neurosci 2014;5(1):8-16
   Google Scholar
• Ojala DS, Amara DP, Schaffer DV. Adeno-associated virus vectors and neurological gene therapy. Neuroscientist 2015;21(1):84-98
   PubMed Web of Science ®Google Scholar
• Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 2013;19(1):40-50
   PubMed Web of Science ®Google Scholar
• Shababi M, Lorson CL, Rudnik-Schoneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat 2014;224(1):15-28
   PubMed Web of Science ®Google Scholar
• Ebert AD, Yu J, Rose FFJr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457(7227):277-80
   PubMed Web of Science ®Google Scholar
• Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001;98(17):9808-13
   PubMed Web of Science ®Google Scholar
• Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004;12(1):59-65
   PubMed Web of Science ®Google Scholar
• Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003;12(19):2481-9
   PubMed Web of Science ®Google Scholar
• Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003;54(5):647-54
   PubMed Web of Science ®Google Scholar
• Tsai LK, Tsai MS, Ting CH, Li H. Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 2008;86(11):1243-54
   PubMed Web of Science ®Google Scholar
• Lesbordes JC, Cifuentes-Diaz C, Miroglio A, et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet 2003;12(11):1233-9
   PubMed Web of Science ®Google Scholar
• Bosch-Marce M, Wee CD, Martinez TL, et al. Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum Mol Genet 2011;20(9):1844-53
   Google Scholar
• Farooq F, Molina FA, Hadwen J, et al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest 2011;121(8):3042-50
   PubMed Web of Science ®Google Scholar
• Brichta L, Holker I, Haug K, et al. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006;59(6):970-5
   PubMed Web of Science ®Google Scholar
• Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006;67(3):500-1
   Google Scholar
• Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE 2009;4(5):e5268
   PubMed Web of Science ®Google Scholar
• Darbar IA, Plaggert PG, Resende MB, et al. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol 2011;11:36
   PubMed Web of Science ®Google Scholar
• Kissel JT, Elsheikh B, King WM, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve 2014;49(2):187-92
   PubMed Web of Science ®Google Scholar
• Swoboda KJ, Scott CB, Crawford TO, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010;5(8):e12140
   PubMed Web of Science ®Google Scholar
• Kissel JT, Scott CB, Reyna SP, et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One 2011;6(7):e21296
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004;14(2):130-5
   PubMed Web of Science ®Google Scholar
• Mercuri E, Bertini E, Messina S, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007;68(1):51-5
   PubMed Web of Science ®Google Scholar
• Tiziano FD, Lomastro R, Pinto AM, et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 2010;47(12):856-8
   PubMed Web of Science ®Google Scholar
• Angelozzi C, Borgo F, Tiziano FD, et al. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 2008;45(1):29-31
   PubMed Web of Science ®Google Scholar
• Kinali M, Mercuri E, Main M, et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002;59(4):609-10
   PubMed Web of Science ®Google Scholar
• Pane M, Staccioli S, Messina S, et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008;18(7):536-40
   PubMed Web of Science ®Google Scholar
• Liang WC, Yuo CY, Chang JG, et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008;268(1-2):87-94
   Google Scholar
• Chen TH, Chang JG, Yang YH, et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology 2010;75(24):2190-7
   PubMed Web of Science ®Google Scholar
• Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003;60(11):1601-3
   PubMed Web of Science ®Google Scholar
• Abbara C, Estournet B, Lacomblez L, et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. Br J Clin Pharmacol 2011;71(3):403-10
   PubMed Web of Science ®Google Scholar
• Kirschner J, Dessaud E, André C, et al. Results of a phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3- to 25-year-old spinal muscular atrophy patients. Neuropediatrics 2014;45(S 01):fp026
   Google Scholar
• Shababi M, Glascock J, Lorson CL. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum Gene Ther 2011;22(2):135-44
   Google Scholar
• Coady TH, Lorson CL. Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J Neurosci 2010;30(1):126-30
   PubMed Web of Science ®Google Scholar
• Coady TH, Shababi M, Tullis GE, Lorson CL. Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol Ther 2007;15(8):1471-8
   Google Scholar
• Tsai LK, Chen CL, Ting CH, et al. Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Mol Ther 2014;22(8):1450-9
   Google Scholar
• Singh NK, Singh NN, Androphy EJ, Singh RN. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006;26(4):1333-46
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24(15):1634-44
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011;3(72):72ra18
   PubMed Web of Science ®Google Scholar
• Available from: http://www.isispharm.com
   Google Scholar
• A Study to Assess the Efficacy and Safety of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy. Available from: https://clinicaltrials.gov/ct2/show/NCT02193074
   Google Scholar
• A Study of Multiple Doses of ISIS SMNRx (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE). Available from: https://clinicaltrials.gov/ct2/show/NCT02386553
   Google Scholar
• Nanou A, Azzouz M. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 2009;175:187-200
   PubMed Web of Science ®Google Scholar
• Azzouz M, Le T, Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004;114(12):1726-31
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010;120(4):1253-64
   PubMed Web of Science ®Google Scholar
• Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010;2(35):35ra42
   PubMed Web of Science ®Google Scholar
• Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011;20(4):681-93
   PubMed Web of Science ®Google Scholar
• Benkhelifa-Ziyyat S, Besse A, Roda M, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 2013;21(2):282-90
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 2014;25(7):619-30
   PubMed Web of Science ®Google Scholar
• Samaranch L, San Sebastian W, Kells AP, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 2014;22(2):329-37
   PubMed Web of Science ®Google Scholar
• Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 2010;19(20):3895-905
   PubMed Web of Science ®Google Scholar
• Duque SI, Arnold WD, Odermatt P, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol 2015;77(3):399-414
   PubMed Web of Science ®Google Scholar
• Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1. Available from: https://clinicaltrials.gov/ct2/show/NCT02122952
   Google Scholar
• Seo J, Howell MD, Singh NN, Singh RN. Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta 2013;1832(12):2180-90
   PubMed Web of Science ®Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011;378(9791):595-605
   PubMed Web of Science ®Google Scholar
• Narver HL, Kong L, Burnett BG, et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann Neurol 2008;64(4):465-70
   PubMed Web of Science ®Google Scholar
• Grondard C, Biondi O, Armand AS, et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci 2005;25(33):7615-22
   PubMed Web of Science ®Google Scholar
• Lewelt A, Krosschell KJ, Stoddard GJ, et al. Resistance strength training exercise in children with spinal muscular atrophy. Muscle nerve 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Finkel R, Day J, Chiriboga C, et al. Results of a phase 2 open-label study of ISIS-SMNRx in patients with infantile (type 1) spinal muscular atrophy (S6.003). Neurology 2014;82(10 Suppl):S6.003
   Google Scholar
• Darras B, Chiriboga C, Swoboda K, et al. G.O.18: Results of a phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy. Neuromuscul Disord 2014;24(9–10):920
   Google Scholar
• Kirschner J, Schorling D, Hauschke D, et al. Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study. Neuromuscul Disord 2014;24(2):134-42
   PubMed Web of Science ®Google Scholar
• Tzeng AC, Cheng J, Fryczynski H, et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil 2000;79(5):435-40
   Google Scholar
• Kato Z, Okuda M, Okumura Y, et al. Oral administration of the thyrotropin-releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy. J Child Neurol 2009;24(8):1010-12
   Google Scholar
• Torres-Benito L, Ruiz R, Tabares L. Synaptic defects in spinal muscular atrophy animal models. Dev Neurobiol 2012;72(1):126-33
   Google Scholar
• Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 2015;23(3):477-87
   PubMed Web of Science ®Google Scholar